BIOMAT Database Logo BIOMAT Database Logo

[Neoadjuvant treatment in human epidermal growth factor receptor 2-positive breast cancer]. 2015

Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Breast Disease Center, Peking University First Hospital, Beijing 100034, China.

Breast cancer is the most prevalent malignancy among females worldwide. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer represents a subtype with aggressive behavior, poor response to treatment and unfavorable prognosis. Anti-HER2-based neoadjuvant treatment has improved clinical outcomes of patients with HER2-positive disease. Pathological complete response (pCR) after neoadjuvant treatment indicates a favorable prognosis. With the development of HER2-targeted therapy and neoadjuvant treatment, numerous studies focus on the predictive factors of pCR or therapeutic resistance of anti-HER2 therapy. Identification of novel predictive factors in HER2-positive breast cancer, such as tumor-infiltrating lymphocytes, will be helpful for clinical decision.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D018719 Receptor, ErbB-2 A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. HER-2 Proto-Oncogene Protein,Proto-Oncogene Protein HER-2,Proto-Oncogene Protein p185(neu),c-erbB-2 Protein,erbB-2 Proto-Oncogene Protein,erbB-2 Receptor Protein-Tyrosine Kinase,neu Proto-Oncogene Protein,Antigens, CD340,CD340 Antigen,Erb-b2 Receptor Tyrosine Kinases,Metastatic Lymph Node Gene 19 Protein,Neu Receptor,Oncogene Protein HER-2,Proto-Oncogene Proteins c-erbB-2,Proto-oncogene Protein Neu,Receptor, Neu,Receptors, erbB-2,Tyrosine Kinase-type Cell Surface Receptor HER2,p185(c-neu),p185erbB2 Protein,CD340 Antigens,Erb b2 Receptor Tyrosine Kinases,ErbB-2 Receptor,HER 2 Proto Oncogene Protein,Oncogene Protein HER 2,Proto Oncogene Protein HER 2,Proto Oncogene Proteins c erbB 2,Proto-Oncogene Protein, HER-2,Proto-Oncogene Protein, erbB-2,Proto-Oncogene Protein, neu,Tyrosine Kinase type Cell Surface Receptor HER2,c erbB 2 Protein,erbB 2 Proto Oncogene Protein,erbB 2 Receptor Protein Tyrosine Kinase,erbB-2 Receptors,neu Proto Oncogene Protein
D020360 Neoadjuvant Therapy Preliminary cancer therapy (chemotherapy, radiation therapy, hormone/endocrine therapy, IMMUNOTHERAPY, HYPERTHERMIA, INDUCED etc.) that is given before the main therapy. Neoadjuvant Chemoradiation,Neoadjuvant Chemoradiation Therapy,Neoadjuvant Chemoradiation Treatment,Neoadjuvant Chemoradiotherapy,Neoadjuvant Chemotherapy,Neoadjuvant Chemotherapy Treatment,Neoadjuvant Radiation,Neoadjuvant Radiation Therapy,Neoadjuvant Radiation Treatment,Neoadjuvant Radiotherapy,Neoadjuvant Systemic Therapy,Neoadjuvant Systemic Treatment,Neoadjuvant Treatment,Chemoradiation Therapy, Neoadjuvant,Chemoradiation Treatment, Neoadjuvant,Chemoradiation, Neoadjuvant,Chemoradiotherapy, Neoadjuvant,Chemotherapy Treatment, Neoadjuvant,Chemotherapy, Neoadjuvant,Neoadjuvant Chemoradiation Therapies,Neoadjuvant Chemoradiation Treatments,Neoadjuvant Chemoradiations,Neoadjuvant Chemoradiotherapies,Neoadjuvant Chemotherapies,Neoadjuvant Chemotherapy Treatments,Neoadjuvant Radiation Therapies,Neoadjuvant Radiation Treatments,Neoadjuvant Radiations,Neoadjuvant Radiotherapies,Neoadjuvant Systemic Therapies,Neoadjuvant Systemic Treatments,Neoadjuvant Therapies,Neoadjuvant Treatments,Radiation Therapy, Neoadjuvant,Radiation Treatment, Neoadjuvant,Radiation, Neoadjuvant,Radiotherapy, Neoadjuvant,Systemic Therapy, Neoadjuvant,Systemic Treatment, Neoadjuvant,Therapy, Neoadjuvant,Therapy, Neoadjuvant Chemoradiation,Therapy, Neoadjuvant Radiation,Therapy, Neoadjuvant Systemic,Treatment, Neoadjuvant,Treatment, Neoadjuvant Chemoradiation,Treatment, Neoadjuvant Chemotherapy,Treatment, Neoadjuvant Radiation,Treatment, Neoadjuvant Systemic

Related Publications

Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
September 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.
April 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer.
January 2022, Scientific reports,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
December 2005, American journal of clinical oncology,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Recent Advances and Strategies.
March 2024, JCO oncology practice,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
PIK3CA genotype and treatment decisions in human epidermal growth factor receptor 2-positive breast cancer.
April 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
February 2023, Current opinion in obstetrics & gynecology,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
January 2022, Cancer control : journal of the Moffitt Cancer Center,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
May 2015, Expert opinion on biological therapy,
Yinhua Liu, and Shiwei Liu, and Hong Zhang, and Ling Xu, and Ting Li, and Xuening Duan
Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer.
February 2014, Current opinion in obstetrics & gynecology,
Copied contents to your clipboard!